کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6257784 1612958 2014 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Research reportNeuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine
ترجمه فارسی عنوان
گزارش تحقیق اثرات نوروپروتئینی آگونیسم های آلفا و گاما گیرنده فعال پرولیفیزوما فعال در مدل پارکینسونی ناشی از غیر متداول 1-متیل-4-فنیل -1،2،3،6-تتراهیپروپیدیدین
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی علوم اعصاب رفتاری
چکیده انگلیسی


- Pioglitazone and fenofibrate protected against behavioral impairments caused by MPTP.
- Both drugs protected against dopaminergic neurons death caused by MPTP.
- Both drugs protected against the increase of caspase-3 in SNpc caused by MPTP.

A large body of evidence suggests that peroxisome proliferator-activated receptor (PPAR) agonists may improve some of the pathological features of Parkinson's disease (PD). In the present study, we evaluated the effects of the PPAR-α agonist fenofibrate (100 mg/kg) and PPAR-γ agonist pioglitazone (30 mg/kg) in a rat model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP). Male Wistar rats were pretreated with both drugs for 5 days and received an infusion of MPTP. The experiments were divided into two parts. First, 1, 7, 14, and 21 days after surgery, the animals were submitted to the open field test. On days 21 and 22, the rats were subjected to the forced swim test and two-way active avoidance task. In the second part of the study, 24 h after neurotoxin administration, immunohistochemistry was performed to assess tyrosine hydroxylase activity. The levels of dopamine and its metabolites in the striatum were determined using high-performance liquid chromatography, and fluorescence detection was used to assess caspase-3 activation in the substantia nigra pars compacta (SNpc). Both fenofibrate as pioglitazone protected against hypolocomotion, depressive-like behavior, impairment of learning and memory, and dopaminergic neurodegeneration caused by MPTP, with dopaminergic neuron loss of approximately 33%. Fenofibrate and pioglitazone also protected against the increased activation of caspase-3, an effector enzyme of the apoptosis cascade that is considered one of the pathological features of PD. Thus, PPAR agonists may contribute to therapeutic strategies in PD.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Behavioural Brain Research - Volume 274, 1 November 2014, Pages 390-399
نویسندگان
, , , , , , , , ,